Donaco International Limited

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, ALL.AX has a market cap of 43.1B. Regarding current trading prices, DNA.AX is priced at A$0.04, while ALL.AX trades at A$68.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas ALL.AX's P/E ratio is 39.78. In terms of profitability, DNA.AX's ROE is +0.24%, compared to ALL.AX's ROE of +0.20%. Regarding short-term risk, DNA.AX is less volatile compared to ALL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check ALL.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, TLC.AX has a market cap of 11.9B. Regarding current trading prices, DNA.AX is priced at A$0.04, while TLC.AX trades at A$5.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas TLC.AX's P/E ratio is 28.26. In terms of profitability, DNA.AX's ROE is +0.24%, compared to TLC.AX's ROE of +1.13%. Regarding short-term risk, DNA.AX is less volatile compared to TLC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check TLC.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, TAH.AX has a market cap of 1.7B. Regarding current trading prices, DNA.AX is priced at A$0.04, while TAH.AX trades at A$0.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas TAH.AX's P/E ratio is -2.48. In terms of profitability, DNA.AX's ROE is +0.24%, compared to TAH.AX's ROE of -0.55%. Regarding short-term risk, DNA.AX is less volatile compared to TAH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check TAH.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, SKC.AX has a market cap of 680.4M. Regarding current trading prices, DNA.AX is priced at A$0.04, while SKC.AX trades at A$0.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas SKC.AX's P/E ratio is -5.26. In terms of profitability, DNA.AX's ROE is +0.24%, compared to SKC.AX's ROE of -0.12%. Regarding short-term risk, DNA.AX is less volatile compared to SKC.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check SKC.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, JIN.AX has a market cap of 647.8M. Regarding current trading prices, DNA.AX is priced at A$0.04, while JIN.AX trades at A$10.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas JIN.AX's P/E ratio is 15.98. In terms of profitability, DNA.AX's ROE is +0.24%, compared to JIN.AX's ROE of +0.36%. Regarding short-term risk, DNA.AX is less volatile compared to JIN.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check JIN.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, PBH.AX has a market cap of 409.3M. Regarding current trading prices, DNA.AX is priced at A$0.04, while PBH.AX trades at A$1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas PBH.AX's P/E ratio is -17.36. In terms of profitability, DNA.AX's ROE is +0.24%, compared to PBH.AX's ROE of -1.93%. Regarding short-term risk, DNA.AX is less volatile compared to PBH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check PBH.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, AGI.AX has a market cap of 336.8M. Regarding current trading prices, DNA.AX is priced at A$0.04, while AGI.AX trades at A$1.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas AGI.AX's P/E ratio is 11.11. In terms of profitability, DNA.AX's ROE is +0.24%, compared to AGI.AX's ROE of -0.03%. Regarding short-term risk, DNA.AX is less volatile compared to AGI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check AGI.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, BBT.AX has a market cap of 317.9M. Regarding current trading prices, DNA.AX is priced at A$0.04, while BBT.AX trades at A$0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas BBT.AX's P/E ratio is -1.82. In terms of profitability, DNA.AX's ROE is +0.24%, compared to BBT.AX's ROE of -1.28%. Regarding short-term risk, DNA.AX is less volatile compared to BBT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check BBT.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, SGR.AX has a market cap of 263.8M. Regarding current trading prices, DNA.AX is priced at A$0.04, while SGR.AX trades at A$0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas SGR.AX's P/E ratio is -0.12. In terms of profitability, DNA.AX's ROE is +0.24%, compared to SGR.AX's ROE of -2.92%. Regarding short-term risk, DNA.AX is less volatile compared to SGR.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check SGR.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, RCT.AX has a market cap of 179.8M. Regarding current trading prices, DNA.AX is priced at A$0.04, while RCT.AX trades at A$3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas RCT.AX's P/E ratio is 18.05. In terms of profitability, DNA.AX's ROE is +0.24%, compared to RCT.AX's ROE of +0.46%. Regarding short-term risk, DNA.AX and RCT.AX have similar daily volatility (0.00).Check RCT.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, BET.AX has a market cap of 159.3M. Regarding current trading prices, DNA.AX is priced at A$0.04, while BET.AX trades at A$0.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas BET.AX's P/E ratio is -3.62. In terms of profitability, DNA.AX's ROE is +0.24%, compared to BET.AX's ROE of -0.41%. Regarding short-term risk, DNA.AX is less volatile compared to BET.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check BET.AX's competition here

DNA.AX plays a significant role within the Consumer Cyclical sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, DNA.AX stands at 54.3M. In comparison, AQS.AX has a market cap of 35.2M. Regarding current trading prices, DNA.AX is priced at A$0.04, while AQS.AX trades at A$0.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

DNA.AX currently has a P/E ratio of 1.47, whereas AQS.AX's P/E ratio is 19.00. In terms of profitability, DNA.AX's ROE is +0.24%, compared to AQS.AX's ROE of -0.15%. Regarding short-term risk, DNA.AX is less volatile compared to AQS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for DNA.AX.Check AQS.AX's competition here